NZ708537A - Method for the preparation of human albumin with reduced level of dissolved oxygen - Google Patents
Method for the preparation of human albumin with reduced level of dissolved oxygenInfo
- Publication number
- NZ708537A NZ708537A NZ708537A NZ70853715A NZ708537A NZ 708537 A NZ708537 A NZ 708537A NZ 708537 A NZ708537 A NZ 708537A NZ 70853715 A NZ70853715 A NZ 70853715A NZ 708537 A NZ708537 A NZ 708537A
- Authority
- NZ
- New Zealand
- Prior art keywords
- preparation
- dissolved oxygen
- human albumin
- reduced level
- albumin
- Prior art date
Links
- 102000008100 Human Serum Albumin Human genes 0.000 title abstract 3
- 108091006905 Human Serum Albumin Proteins 0.000 title abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title abstract 2
- 229910052760 oxygen Inorganic materials 0.000 title abstract 2
- 239000001301 oxygen Substances 0.000 title abstract 2
- 102000009027 Albumins Human genes 0.000 abstract 2
- 108010088751 Albumins Proteins 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430824A ES2524516B1 (es) | 2014-05-29 | 2014-05-29 | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ708537A true NZ708537A (en) | 2017-06-30 |
Family
ID=52003454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ708537A NZ708537A (en) | 2014-05-29 | 2015-05-27 | Method for the preparation of human albumin with reduced level of dissolved oxygen |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10350274B2 (enExample) |
| EP (1) | EP2952203B9 (enExample) |
| JP (3) | JP2015224251A (enExample) |
| KR (1) | KR101960729B1 (enExample) |
| CN (1) | CN105315362B (enExample) |
| AR (1) | AR100618A1 (enExample) |
| AU (1) | AU2015202413B2 (enExample) |
| BR (1) | BR102015012091A8 (enExample) |
| CA (1) | CA2890642C (enExample) |
| CL (1) | CL2015001446A1 (enExample) |
| ES (2) | ES2524516B1 (enExample) |
| HU (1) | HUE031823T2 (enExample) |
| IL (1) | IL238898B (enExample) |
| MX (1) | MX362869B (enExample) |
| MY (1) | MY171771A (enExample) |
| NZ (1) | NZ708537A (enExample) |
| PL (1) | PL2952203T3 (enExample) |
| PT (1) | PT2952203T (enExample) |
| RU (1) | RU2657578C2 (enExample) |
| SG (1) | SG10201504137PA (enExample) |
| TW (1) | TWI607018B (enExample) |
| ZA (1) | ZA201503539B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
| ES2900302T3 (es) | 2016-04-28 | 2022-03-16 | Alkahest Inc | Fracciones de plasma como terapia para el crecimiento y la progresión del tumor |
| HRP20211628T1 (hr) | 2016-08-18 | 2022-02-04 | Alkahest, Inc. | Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem |
| BR112019022402A2 (pt) | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
| WO2020018343A1 (en) | 2018-07-20 | 2020-01-23 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| MX2021004755A (es) | 2018-10-26 | 2021-06-08 | Alkahest Inc | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. |
| CN109627322A (zh) * | 2019-01-07 | 2019-04-16 | 中国科学院过程工程研究所 | 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法 |
| CN114667151B (zh) | 2019-11-04 | 2025-05-23 | 万能溶剂有限公司 | 用于肌肉再生的血浆级分 |
| WO2021102032A1 (en) | 2019-11-20 | 2021-05-27 | Alkahest, Inc. | Blood plasma fractions for use in liver regeneration |
| WO2024200553A1 (en) | 2023-03-29 | 2024-10-03 | Grifols Worldwide Operations Limited | COMPOSITIONS AND METHODS OF PREPARATION OF BLOOD PLASMA PRODUCTS WITH REDUCED LEVELS OF FceRIß AUTOANTIBODIES |
| CN118166053B (zh) * | 2024-03-15 | 2025-02-07 | 通化安睿特生物制药股份有限公司 | 一种制备低o-糖基化水平的重组人白蛋白的方法 |
| WO2025230830A1 (en) | 2024-04-29 | 2025-11-06 | Alkahest, Inc. | Compositions of blood plasma fractions and their use in treatment of spinal muscular atrophy (sma) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| JPH07126182A (ja) * | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
| SE9402119D0 (sv) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| JP4254117B2 (ja) * | 2001-03-27 | 2009-04-15 | ニプロ株式会社 | アルブミン溶液収容プラスチック容器 |
| DE60234142D1 (de) * | 2001-03-27 | 2009-12-10 | Nipro Corp | Albuminlösung enthaltender Kunststoffbehälter |
| WO2003002139A1 (fr) * | 2001-06-29 | 2003-01-09 | Asahi Kasei Kabushiki Kaisha | Procede permettant d'ameliorer la stabilite de la preparation de proteines |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| ATE342904T1 (de) * | 2003-08-28 | 2006-11-15 | Nipro Corp | Künstlicher sauerstoffträger und herstellungsverfahren dafür |
| JP5364382B2 (ja) * | 2006-02-07 | 2013-12-11 | シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド | 遊離チオール部分を有するタンパク質の安定化された組成物 |
| ES2294976B1 (es) * | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
| JP5990880B2 (ja) * | 2011-08-31 | 2016-09-14 | 東レ株式会社 | 有用タンパク質組成物およびその製造方法 |
| CN102816230B (zh) * | 2012-08-27 | 2014-02-12 | 同路生物制药股份有限公司 | 人血白蛋白的制备方法 |
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
-
2014
- 2014-05-29 ES ES201430824A patent/ES2524516B1/es not_active Expired - Fee Related
-
2015
- 2015-04-01 HU HUE15382164A patent/HUE031823T2/en unknown
- 2015-04-01 PL PL15382164T patent/PL2952203T3/pl unknown
- 2015-04-01 PT PT153821640T patent/PT2952203T/pt unknown
- 2015-04-01 ES ES15382164.0T patent/ES2601137T3/es active Active
- 2015-04-01 EP EP15382164.0A patent/EP2952203B9/en active Active
- 2015-05-01 CA CA2890642A patent/CA2890642C/en active Active
- 2015-05-06 AU AU2015202413A patent/AU2015202413B2/en active Active
- 2015-05-15 MY MYPI2015701570A patent/MY171771A/en unknown
- 2015-05-18 RU RU2015118453A patent/RU2657578C2/ru active
- 2015-05-19 IL IL238898A patent/IL238898B/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03539A patent/ZA201503539B/en unknown
- 2015-05-21 MX MX2015006407A patent/MX362869B/es active IP Right Grant
- 2015-05-22 CN CN201510264800.9A patent/CN105315362B/zh active Active
- 2015-05-26 SG SG10201504137PA patent/SG10201504137PA/en unknown
- 2015-05-26 TW TW104116876A patent/TWI607018B/zh not_active IP Right Cessation
- 2015-05-26 BR BR102015012091A patent/BR102015012091A8/pt not_active IP Right Cessation
- 2015-05-27 NZ NZ708537A patent/NZ708537A/en not_active IP Right Cessation
- 2015-05-27 AR ARP150101653A patent/AR100618A1/es active IP Right Grant
- 2015-05-28 JP JP2015108569A patent/JP2015224251A/ja active Pending
- 2015-05-28 CL CL2015001446A patent/CL2015001446A1/es unknown
- 2015-05-28 KR KR1020150074568A patent/KR101960729B1/ko active Active
- 2015-05-28 US US14/724,649 patent/US10350274B2/en active Active
-
2018
- 2018-04-27 JP JP2018086673A patent/JP2018115210A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074749A patent/JP2020111614A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ708537A (en) | Method for the preparation of human albumin with reduced level of dissolved oxygen | |
| EA033286B1 (ru) | Способ лечения или отсрочки развития хронической болезни почек | |
| EA201791182A1 (ru) | Новые производные 2'- и/или 5'-аминокислотных эфиров фосфороамидатов 3'-дезоксиаденозина в качестве противораковых соединений | |
| PH12016502150A1 (en) | Method for treating renal cell carcimona | |
| EA201791467A1 (ru) | Водный офтальмологический раствор | |
| WO2013022740A3 (en) | Gpr35 ligands and the uses thereof | |
| PH12016500158A1 (en) | Methods for controlling fucosylation levels in proteins | |
| PH12016502322B1 (en) | Compounds and methods for preventing or treating malaria | |
| MX2015008310A (es) | Procedimiento para el tratamiento de enfermedades relacionadas con el factor inducible por hipoxia (hif) -. | |
| PH12017500563A1 (en) | Stabilized adrenomedullin derivatives and use thereof | |
| EA201791845A1 (ru) | Твердые формы менахинолов | |
| EP3003446A4 (en) | Controlling arterial blood gas concentration | |
| PH12016501326A1 (en) | (s)-3'-methyl-abscisic acid and esters thereof | |
| NZ722725A (en) | Flavour stable beverages | |
| MX374865B (es) | Solución de diálisis. | |
| MY188930A (en) | Treatment process of gas containing zero-valent mercury and mercury separation system | |
| PH12018500339A1 (en) | Lysobactin for use in the treatment of bovine mastitis | |
| EE05766B1 (et) | Meetod suure aktiivkloorisisaldusega desinfektsioonivahendi saamiseks läbivoolu diafragmaelektrolüüserist | |
| MX361559B (es) | Metodo para tratar limo de anodo de plomo. | |
| UA79303U (ru) | Применение таурина как средства стабилизации концентрации итраконазола в плазме крови при лечении грибковых заболеваний | |
| UY36507A (es) | Procedimiento de preparacion de albumina humana con nivel de oxigeno disuelto reducido | |
| UA105659U (uk) | Застосування способу визначення вмісту теофіліну як способу визначення концентрації елетриптану у водному розчині | |
| UA91071U (uk) | Спосіб профілактики та корекції запальних хвороб на донозологічному рівні | |
| EA201700030A1 (ru) | Липид, содержащий докозапентаеновую кислоту | |
| GB2546703A (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2020 BY AJ PARK Effective date: 20190227 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY AJ PARK Effective date: 20200311 |
|
| LAPS | Patent lapsed |